Jump to content

User:Mr. Ibrahem/Venetoclax

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Venetoclax
Clinical data
Trade namesVenclexta, Venclyxto
Other namesGDC-0199, ABT-199, RG-7601
AHFS/Drugs.comMonograph
MedlinePlusa616028
License data
Pregnancy
category
Routes of
administration		By mouth (tablets)
Drug classBCL-2 inhibitor[2]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)[3]
  • US: ℞-only[4]
  • EU: Rx-only[5]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding>99.9%[4]
MetabolismLiver (CYP3A4, CYP3A5)
Elimination half-life~26 hours
ExcretionFeces (>99.9%; 20.8% as unchanged venetoclax)
Identifiers
  • 4-(4-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}-1-piperazinyl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
Chemical and physical data
FormulaC45H50ClN7O7S
Molar mass868.45 g·mol−1
3D model (JSmol)
  • CC1(CCC(=C(C1)c2ccc(cc2)Cl)CN3CCN(CC3)c4ccc(c(c4)Oc5cc6cc[nH]c6nc5)C(=O)NS(=O)(=O)c7ccc(c(c7)[N+](=O)[O-])NCC8CCOCC8)C
  • InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54) COPY
  • Key:LQBVNQSMGBZMKD-UHFFFAOYSA-N

Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).[4][5] It is taken by mouth.[5] It may be used on its own or together with other medications.[5]

Common side effects include low white blood cells, low red blood cell, high potassium, diarrhea, nausea, respiratory infections, and tiredness.[5] Other severe side effects may include sepsis, low potassium, tumor lysis syndrome, and bleeding.[5][2] It interacts with St. John’s wort.[5] It works by attaching to a protein called Bcl-2, blocking its activity, which results in the death of cancer cells.[5]

Venetoclax was approved for medical use in Europe and the United States in 2016.[5][2] In the United Kingdom 112 tablets of 100 mg costs the NHS about £4,800.[6] This amount in the United States costs about 12,600 USD as of 2021.[7]

References[edit]

  1. ^ a b "Venetoclax (Venclexta) Use During Pregnancy". Drugs.com. 29 May 2019. Archived from the original on 19 January 2021. Retrieved 25 April 2020.
  2. ^ a b c "Venetoclax Monograph for Professionals". Drugs.com. Archived from the original on 31 May 2021. Retrieved 13 September 2021.
  3. ^ "Venclyxto 10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 21 April 2020. Archived from the original on 26 April 2021. Retrieved 25 April 2020.
  4. ^ a b c d "Venclexta- venetoclax kit Venclexta- venetoclax tablet, film coated". DailyMed. 12 November 2019. Archived from the original on 15 June 2020. Retrieved 25 April 2020.
  5. ^ a b c d e f g h i j k l "Venclyxto EPAR". European Medicines Agency (EMA). Archived from the original on 16 April 2020. Retrieved 25 April 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1066. ISBN 978-0-85711-369-6.
  7. ^ "Venclexta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 January 2021. Retrieved 13 September 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Venetoclax&oldid=1154231296"